By G. Vigo. Cabrini College. 2019.
Drug addiction counseling may happen individually order 20 mg fluoxetine with mastercard, with loved ones or in a group setting order fluoxetine 20 mg on-line. The following types of drug addiction therapy are evidence-based as recognized by the National Institute on Drug Abuse: Cognitive Behavioral Therapy (CBT) - addresses addiction-related behaviors by identifying them and learning skills to modify them discount 20 mg fluoxetine overnight delivery. People who received CBT have been shown to retain their treatment gains over the following year. Community Reinforcement Approach (CRA) - focuses on improving relationships, learning life and vocational skills, and creating a new social network. This is combined with frequent drug testing whereby drug-free screenings are rewarded with vouchers which are exchangeable for health-related goods. CRA has been shown to increase patient participation in drug addiction counseling and increase periods of drug abstinence. Motivational Enhancement Therapy (MET) - focuses on increasing the internal motivation towards treatment and addiction behavior change. MET is most successful at increasing patient participation in drug addiction therapy and treatment. The Matrix Model - a multi-approach system built on promoting patient self-esteem, self-worth and a positive relationship between the therapist and patient. The therapist is viewed as a teacher and coach and uses their relationship to reinforce positive change. The Matrix Model drug addiction therapy contains detailed manuals, worksheets and exercises drawing from other types of therapy. The Matrix Model has been shown effective particularly when treating stimulant abuse. The three key aspects of this type of drug addiction counseling are: acceptance of drug addiction; surrendering oneself to a higher power; active involvement in 12-step activities. FT has been shown effective, particularly in cases of alcohol addiction. Behavioral Couples Therapy (BCT) - creates a sobriety/(drug) abstinence contract for the couple and uses behavioral therapies. BCT has been shown effective at increasing treatment engagement and drug abstinence as well as decreasing drug-related family and legal problems at a 1-year follow-up. Other, more general types of drug addiction therapy are also available in the forms of psychotherapy and group therapy. Psychotherapy is an appropriate drug addiction therapy particularly when past traumatic events are involved. Places providing specific types of drug addiction therapy can found through their respective professional organizations or through substance abuse treatment centers. Drug addiction therapy is always best offered by experts in the particular form of drug addiction counseling. Some types of drug addiction therapy have certifications and professional organizations associated with them such as the National Association of Cognitive-Behavioral Therapists and the Association for Behavior Analysis. Drug addiction counseling and therapy varies in length from only a few sessions, like in the case of MET, to 12 - 16 sessions for CBT and BCT. Some drug addiction therapy lasts more than 24 weeks, as is the case with CRA and the Matrix Model. When drug addiction therapy is provided as part of a drug addiction program, the cost of the drug addiction counseling is included in the cost of the drug addiction program. Other drug addiction counseling may be offered through community services on a sliding payment scale or free-of-charge. For private drug addiction therapy sessions, one hour may cost $150 or more, with health insurance paying some or all of the cost. Drug addiction facts and drug addiction statistics have been tracked by a variety of groups in the United States and worldwide. In spite of this, drug addiction statistics are still considered inaccurate because of the way in which they are collected (self-reporting) and the limited sample size and sample type. Drug addiction statistics collected as a result of emergency room visits or entry into treatment are considered representative of people in that situation, however. Facts about drug addiction, as well as drug addiction statistics, are collected by The Substance Abuse and Mental Health Services Administration (SAMHSA). The government agency authored the National Survey on Drug Use and Health. Here are some staggering drug addiction facts, based on statistics from 2009: 23. Facts about drug addiction show cigarette usage has also declined among teens. However, recently, concern has been raised over teens smoking tobacco from a hookah pipe or cigar. When asked, 17% of 12-graders reported hookah smoking and 23% reported smoking small cigars. As the above drug addiction statistic shows, almost one-in-ten people sought treatment for substance abuse in 2009. Drug addiction facts collected in 2008 suggest the vast majority of these, over 40%, involve alcohol abuse. Of those admitted to treatment in 2008, the following drug addiction statistics provide an inside look into the drug problem in America:The largest age group is between ages 20 - 29, making up almost 30% of admissionsAges 30 - 39 made up 23% of admissions, almost tied with ages 40 - 49 at 24%Above the age of 50, admission rates fall dramaticallyThe top three ethnicities of admissions were: white (60%), African-American (21%) and Hispanic (14%)Further drug addiction statistics garnered from the 2009 National Survey on Drug Use and Health (SAMHSA) include:In 2009, 12% of people aged 12 or older admitted to driving under the influence of alcohol in the last yearThis is a reduction from 2002, where 14. One can abuse drugs without necessarily being addicted to drugs. The drug abuse definition centers more around the way a person uses drugs, while the drug addiction definition includes the use of drugs and also the psychological and physiological effects the drug has on the body. Central to the understanding of drug abuse and addiction is the idea of tolerance. When a person starts using a drug, they typically use a small amount to receive pleasurable effects, or a "high. In drug abuse and addiction, creation of tolerance depends on the drug used, the amount that is used and the frequency with which it is used. Drug tolerance can be both psychological and physiological. The definition of drug abuse does not have drug tolerance as a factor. The following are drug abuse symptoms: Drug use has negatively impacted performance in work or schoolRisky acts endangering the drug user or others are committed as a result of drug use, for example, drinking and drivingContinuation of drug use in spite of the negative consequences drug use is having on relationshipsLegal or financial problems as a result of drug useA drug user may match the drug abuse definition even if only one of the symptoms is present. Drug abuse frequently, but not always, leads to drug addiction. The definition of drug addiction contains aspects of the drug abuse definition in that the user is experiencing negative consequences from drug use and refuses to quit using the drug. However, with drug addiction, the addict has developed a tolerance to the drug, increasing the used amount, and experiences withdrawal symptoms when abstinent. In addition to drug tolerance, here are other drug addiction symptoms:Experiencing withdrawal symptoms when not using the drugIs unable to stop using the drug even after repeated attempts to do soConsumes large and even dangerous amounts of the drugWhile the term "drug addiction" is commonly known, it is not used in the Diagnostic and Statistical Manual of Mental Disorders (DSM). Instead, the DSM defines substance dependence similarly to the drug addiction definition above.
The primary dynamic here is a denial of her feelings generic 20mg fluoxetine fast delivery. If buy fluoxetine 20 mg fast delivery, on the other hand purchase generic fluoxetine pills, she has through one means or another found out that the addict is acting out sexually and confronts him, the addict may attack his partner, telling her that if she was not so (demanding, withholding, out of touch with the times, etc. Most partners describe these processes as "making me feel crazy. In her book, Back From Betrayal: Recovery for Women Involved With Sex Addicted Men, Jennifer Schneider presents a cohesive description of a co-addict. Her main goal in life is to try to figure out what her partner wants, and then give it to him. To assure success at pleasing, she may become extremely sensitive to the momentary mood of her partner. She may constantly worry about what he thinks about her and try extremely hard not to make a mistake. Because of these self-defeating characteristics, the co-addict usually is much more in tune with what someone else wants than with her own wants and needs. The energy expended on such an endeavor can take a heavy toll on the co-addict as she tries repeatedly and unsuccessfully to " keep her man happy. The co-addict, in an effort to please the addict, may do the following things. She may change her hair color, lose/gain weight, quit her job/go to work, or wear sexy underwear. Or she may perform sex acts that are unpleasant or repulsive to her, or attend events that shock and confuse her, swing with others, or expose herself to sexually transmitted diseases. Or, most importantly for a co-addict with children, she may use them and/or ignore them in her efforts to focus on the addict-partner. To "please and keep her man" the co-addict will often attempt to become indispensable to the addict. In their book, Women Who Love Sex Addicts: Help For Healing from the Effects of a Relationship With A Sex Addict, Douglas Weiss and Dianne DeBusk list some of the common fears a co-addict may experience. Nevertheless, the co-addict repeatedly attempts to control the addict with such behaviors as calling or beeping him several times a day in order to find out where he is; checking his wallet for tell-tale evidence; going through credit card bills; checking his shirts for lipstick smudges or his dirty underwear for signs of semen; throwing away pornographic material. She may also attempt to manipulate his behavior with a variety of behaviors of her own, including acting overly understanding and/or becoming a screamer-yeller. Since the disease of sexual addiction is, like any addiction, progressive, that is, it gets more time-consuming and costly as time goes by, eventually the secret life of the sexual addict is discovered or uncovered and the couple experiences a tremendous crisis. Often, the sexual addict will then enter a period of extreme remorse, beg for forgiveness, and promise never to act out again. His promises at the time are probably sincere and most co-addicts want to believe the words. A honeymoon period may follow, including intense sexual activity between the two people. Since, for the co-addict, sex is often a sign of love, she may be lulled into believing everything is really all right, offer forgiveness and bind up her wounded spirit and go on. She is later shattered to discover the unaccounted for time and secrecy has returned. The reason the behavior of both the addict and co-addict cannot be stopped by self-control is that the roots of their behavior go far back, usually to their growing-up period. Typically, the individuals in the coupleship were given unclear, unhelpful and unworkable covert and overt messages by her/his caretakers about trust, about how important s/he is, what to expect from others and how to get needs and wants met. As an adult, this person may struggle to make relationship connections and to solve life problems. However, the messages they were given earlier about how to navigate in life usually fail her/him;they often turn out to be ineffective at best and disastrous or dangerous at worst. Chris and Bobby were introduced to each other one night by mutual friends who were helping Chris celebrate her birthday. She was feeling somewhat vulnerable, not only having had a few drinks to celebrate, but she had just broken up with her boyfriend of two years. When Bobby was introduced to her, sparks between the two of them began to fly immediately. He was charming, attentive, intelligent ; also somewhat inebriated. The emotional pain Chris had experienced since the breakup began to dissolve. When Bobby asked to take her home that night, she felt that something miraculous was happening. Although she declined to have sex, they engaged in some heavy petting. The went out together the next night, and soon they were seeing each other on a regular basis. A sexual relationship developed quickly which Chris described as incredible. Since Bobby had just stepped out to get the mail, the answering machine picked up. Stunned, Chris told Bobby what she had heard, and, in a somewhat irritated manner, he explained that the woman leaving the message was an old girl friend who had been bugging him to get back together and there was nothing to it. He would sometimes make lewd comments under his breath or smile in a trance-like manner. And sometimes at parties Bobby would frequently cozy up to some of the other females and ignore her. Once, he even disappeared for a while during a party, and when Chris looked for him, he was outside in a secluded spot with another woman. When Chris started to confront Bobby about what she was seeing, Bobby dismissed her complaints as "stupid" and said that she was beginning to get on his nerves by being so possessive. She also highlighted her hair and went on a body-wrecking quick weight loss diet to lose 10 pounds. After Chris agreed to and engaged in some sexual activities that Bobby had been asking her to do, but that she had felt uncomfortable in doing, Bobby surprised her by agreeing to get married. At the bachelor party the night before, Bobby got drunk, barely made it through the wedding and reception and quickly passed out once they were in their hotel. Fast forward a few years and a couple of kids later. Chris accuses Bobby of not loving her and the kids and she alternately tries to set things right by being seductive and then angrily telling him how he is hurting her by the way he acts toward her. Exhausted, confused, she wonders just what there is to live for. One day, when opening the mail, she sees a credit card bill that astounds her. She questions everything about herself: her intelligence, her sexuality, her reality. It is important, therefore, to recognize that not only her partner has a disease and has developed an irrational way of living and being, but that she, the co-addict, has as well. Each person will need help in erasing or ameliorating the dysfunctional messages they learned during childhood and adolescence that predisposed him/her to their respective diseases and the unfortunate consequences of the addictions.
The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were anxiety (1 purchase fluoxetine master card. Adverse Reactions Occurring at an Incidence of 2% or More Among SAPHRIS-Treated Bipolar Patients: Adverse reactions associated with the use of SAPHRIS (incidence of 2% or greater discount 20 mg fluoxetine with amex, rounded to the nearest percent cost of fluoxetine, and SAPHRIS incidence greater than placebo) that occurred during acute therapy (up to 3-weeks in patients with bipolar mania) are shown in Table 3. TABLE 3: Adverse Reactions Reported in 2% or More of Subjects in one of the SAPHRIS Dose Groups and Which Occurred at Greater Incidence Than in the Placebo Group in 3-Week Bipolar Mania TrialsMusculoskeletal and connective tissue disordersOther extrapyramidal symptomsExtrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity,parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia). Dystonia: Antipsychotic Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups. Extrapyramidal Symptoms: In the short-term, placebo-controlled schizophrenia and bipolar mania trials, data was objectively collected on the Simpson Angus Rating Scale for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (for akathisia) and the Assessments of Involuntary Movement Scales (for dyskinesias). The mean change from baseline for the all-SAPHRIS 5 mg or 10 mg twice daily treated group was comparable to placebo in each of the rating scale the short-term, placebo-controlled schizophrenia trials, the incidence of reported EPS-related events, excluding events related to akathisia, for SAPHRIS-treated patients was 10% versus 7% for placebo; and the incidence of akathisia-related events for SAPHRIS-treated patients was 6% versus 3% for placebo. In short-term placebo-controlled bipolar mania trials, the incidence of EPS-related events, excluding events related to akathisia, for SAPHRIS-treated patients was 7% versus 2% for placebo; and the incidence of akathisia-related events for SAPHRIS-treated patients was 4% versus 2% for placebo. Glucose: The effects on fasting serum glucose levels in the short-term schizophrenia and bipolar mania trials revealed no clinically relevant mean changes [see also Warnings and Precautions (5. In the short-term placebo-controlled schizophrenia trials, the mean increase in fasting glucose levels for SAPHRIS-treated patients was 3. The proportion of patients with fasting glucose elevations ?-U126 mg/dL (at Endpoint), was 7. In the short-term, placebo-controlled bipolar mania trials, the mean decreases in fasting glucose levels for both SAPHRIS-treated and placebo-treated patients were 0. The proportion of patients with fasting glucose elevations ?-U126 mg/dL (at Endpoint), was 4. In a 52-week, double-blind, comparator-controlled trial of patients with schizophrenia and schizoaffective disorder, the mean increase from baseline of fasting glucose was 2. Lipids: The effects on total cholesterol and fasting triglycerides in the short-term schizophrenia and bipolar mania trials revealed no clinically relevant mean changes. In short-term, placebo-controlled schizophrenia trials, the mean increase in total cholesterol levels for SAPHRIS-treated patients was 0. The proportion of patients with total cholesterol elevations ?-U240 mg/dL (at Endpoint) was 8. In short-term, placebo-controlled bipolar mania trials, the mean increase in total cholesterol levels for SAPHRIS-treated patients was 1. The proportion of patients with total cholesterol elevations ?-U240 mg/dL (at Endpoint) was 8. In short-term, placebo-controlled schizophrenia trials, the mean increase in triglyceride levels for SAPHRIS-treated patients was 3. The proportion of patients with elevations in triglycerides ?-U200 mg/dL (at Endpoint) was 13. In short-term, placebo-controlled bipolar mania trials, the mean decrease in triglyceride levels for SAPHRIS-treated patients was 3. The proportion of patients with elevations in triglycerides ?-U200 mg/dL (at Endpoint) was 15. In a 52-week, double-blind, comparator-controlled trial of patients with schizophrenia and schizoaffective disorder, the mean decrease from baseline of total cholesterol was 6 mg/dL and the mean decrease from baseline of fasting triglycerides was 9. Transaminases: Transient elevations in serum transaminases (primarily ALT) in the short-term schizophrenia and bipolar mania trials were more common in treated patients but mean changes were not clinically relevant. In short-term, placebo-controlled schizophrenia trials, the mean increase in transaminase levels for SAPHRIS-treated patients was 1. The proportion of patients with transaminase elevations ?-U3 times ULN (at Endpoint) was 0. In short-term, placebo-controlled bipolar mania trials, the mean increase in transaminase levels for SAPHRIS-treated patients was 8. The proportion of patients with transaminase elevations ?-U3 times upper limit of normal (ULN) (at Endpoint) was 2. In a 52-week, double-blind, comparator-controlled trial of patients with schizophrenia and schizoaffective disorder, the mean increase from baseline of ALT was 1. Prolactin: The effects on prolactin levels in the short-term schizophrenia and bipolar mania trials revealed no clinically relevant changes in mean change in baseline. In short-term, placebo-controlled schizophrenia trials, the mean decreases in prolactin levels were 6. The proportion of patients with prolactin elevations ?-U4 times ULN (at Endpoint) were 2. In short-term, placebo-controlled bipolar mania trials, the mean increase in prolactin levels was 4. The proportion of patients with prolactin elevations =?-U4 times ULN (at Endpoint) were 2. In a long-term (52-week), double-blind, comparator-controlled trial of patients with schizophrenia and schizoaffective disorder, the mean decrease in prolactin from baseline for SAPHRIS-treated patients was 26. Other Adverse Reactions Observed During the Premarketing Evaluation of SAPHRIS: Following is a list of MedDRA terms that reflect adverse reactions reported by patients treated with sublingual SAPHRIS at multiple doses of ?-U5 mg twice daily during any phase of a trial within the database of adult patients. The reactions listed are those that could be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds. Reactions already listed in other parts of Adverse Reactions (6), or those considered in Warnings and Precautions (5) or Overdosage (10) are not included. Although the reactions reported occurred during treatment with SAPHRIS, they were not necessarily caused by it. Reactions are further categorized by MedDRA system organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing); those occurring in 1/100 to 1/1000 patients; and those occurring in fewer than 1/1000 patients. Blood and lymphatic disorders: <1/1000 patients:thrombocytopenia;?-U1/1000 patients and <1/100 patients:anemiaCardiac disorders: ?-U1/1000 patients and <1/100 patients: tachycardia, temporary bundle branch blockEye disorders: ?-U1/1000 patients and <1/100 patients: accommodation disorderGastrointestinal disorders: ?-U1/1000 patients and <1/100 patients: oral paraesthesia, glossodynia, swollen tongueGeneral disorders: <1/1000 patients: idiosyncratic drug reactionInvestigations:?-U1/1000 patients and <1/100 patients:hyponatremiaNervous system disorders: ?-U1/1000 patients and <1/100 patients: dysarthriaThe risks of using SAPHRIS in combination with other drugs have not been extensively evaluated. Given the primary CNS effects of SAPHRIS, caution should be used when it is taken in combination with other centrally-acting drugs or alcohol. Because of its ~a1-adrenergic antagonism with potential for inducing hypotension, SAPHRIS may enhance the effects of certain antihypertensive agents. Asenapine is cleared primarily through direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450isoenzymes (predominantly CYP1A2). The potential effects of inhibitors of several of these enzyme pathways on asenapine clearance were studied. TABLE 4: Summary of Effect of Coadministered Drugs on Exposure to Asenapine in Healthy VolunteersCoadministered drug (Postulated effect on CYP450/UGT)Effect on asenapine pharmacokineticsCoadminister with caution*Imipramine (CYP1A2/2C19/3A4 inhibitor)No SAPHRIS dose adjustment requiredCimetidine (CYP3A4/2D6/1A2 inhibitor)Coadministration with CYP2D6 Substrates: In vitro studies indicate that asenapine weakly inhibits CYP2D6. Following coadministration of dextromethorphan and SAPHRIS in healthy subjects, the ratio of dextrorphan/dextromethorphan (DX/DM) as a marker of CYP2D6 activity was measured.
Hypoglycemia is more likely to occur when caloric intake is deficient purchase fluoxetine 10mg free shipping, after severe or prolonged exercise buy discount fluoxetine 20 mg line, when alcohol is ingested purchase on line fluoxetine, or when more than one glucose-lowering drug is used. Because of the long half-life of chlorpropamide, patients who become hypoglycemic during therapy require careful supervision of the dose and frequent feedings for at least 3 to 5 days. Hospitalization and intravenous glucose may be necessary. When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a loss of control may occur. At such times, it may be necessary to discontinue Diabinese and administer insulin. The effectiveness of any oral hypoglycemic drug, including Diabinese, in lowering blood glucose to a desired level decreases in many patients over a period of time, which may be due to progression of the severity of the diabetes or to diminished responsiveness to the drug. This phenomenon is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective in an individual patient when first given. Adequate adjustment of dose and adherence to diet should be assessed before classifying a patient as a secondary failure. The safety and effectiveness of Diabinese in patients aged 65 and over has not been properly evaluated in clinical studies. Adverse event reporting suggests that elderly patients may be more prone to developing hypoglycemia and/or hyponatremia when using Diabinese. Although the underlying mechanisms are unknown, abnormal renal function, drug interaction and poor nutrition appear to contribute to these events. Patients should be informed of the potential risks and advantages of Diabinese and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained. Patients should be instructed to contact their physician promptly if they experience symptoms of hypoglycemia or other adverse reactions. In initiating treatment for type 2 diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible. Use of Diabinese or other antidiabetic medications must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitution or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may be transient, thus requiring only short-term administration of Diabinese or other antidiabetic medications. Maintenance or discontinuation of Diabinese or other antidiabetic medications should be based on clinical judgment using regular clinical and laboratory evaluations. Measurement of glycosylated hemoglobin should be performed and goals assessed by the current standard of care. Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because Diabinese belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. In post marketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency. The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving Diabinese, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving Diabinese, the patient should be observed closely for loss of control. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with intravenous, topical, or vaginal preparations of miconazole is not known. In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol. Moderate to large amounts of alcohol may increase the risk of hypoglycemia (ref. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Diabinese, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving Diabinese, the patient should be observed closely for hypoglycemia. Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution. Studies with Diabinese have not been conducted to evaluate carcinogenic or mutagenic potential. Rats treated with continuous Diabinese therapy for 6 to 12 months showed varying degrees of suppression of spermatogenesis at a dose level of 250 mg/kg (five times the human dose based on body surface area). The extent of suppression seemed to follow that of growth retardation associated with chronic administration of high-dose Diabinese in rats. The human dose of chlorpropamide is 500 mg/day (300 mg/M2). Six- and 12-month toxicity work in the dog and rat, respectively, indicates the 150 mg/kg is well tolerated. Therefore, the safety margins based upon body-surface-area comparisons are three times human exposure in the rat and 10 times human exposure in the dog. Animal reproductive studies have not been conducted with Diabinese. It is also not known whether Diabinese can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Diabinese should be given to a pregnant woman only if the potential benefits justify the potential risk to the patient and fetus. Because data suggest that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible. Prolonged severe hypoglycemia (4 to 10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery.
10 of 10 - Review by G. Vigo
Votes: 304 votes
Total customer reviews: 304